Skip to main content
. 2021 Feb 15;131(4):e139542. doi: 10.1172/JCI139542

Figure 3. Inhibition of IDH1-R132H increases PD-L1 expression levels on mouse mIDH1 glioma cells.

Figure 3

(A) Experimental design to characterize PD-L1 expression on glioma cells and immune cells. (B) Representative histograms displaying PD-L1 expression levels on CD45–/Nestin+/Katushka+ glioma cells or (C) on CD45+ immune cells in the TME (purple, WT-IDH tumor; black, mIDH1 tumor; blue, mIDH1 tumor treated with AGI-5198). **P < 0.01; ***P < 0.001; 1-way ANOVA. Bars represent mean ± SEM (n = 4 biological replicates). (D) Immunofluorescence staining of Nestin (green), PD-L1 (red), and DAPI (blue) in 5 μm brain tumor sections from WT-IDH (24 dpi), mIDH1 (35 dpi), or mIDH1+AGI-5198 (43 dpi) animals. (E) Quantification of PD-L1 promoter methylation levels in mIDH1 or WT-IDH mouse-NSs after treatment with 1.5 μM AGI-5198 or vehicle. **P < 0.01; 1-way ANOVA. Bars represent mean ± SEM (n = 3 technical replicates).